|
Mental Depression
|
0.210 |
Biomarker
|
disease |
BEFREE |
The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat.
|
30195732 |
2018 |
|
Mental Depression
|
0.210 |
Biomarker
|
disease |
RGD |
Hepatic drug metabolizing profile of Flinders Sensitive Line rat model of depression.
|
20595028 |
2010 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A combined analysis of genetically correlated traits identifies 187 loci and a role for neurogenesis and myelination in intelligence.
|
29326435 |
2019 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways.
|
31374203 |
2019 |
|
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways.
|
31374203 |
2019 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function.
|
29844566 |
2018 |
|
mathematical ability
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.
|
30038396 |
2018 |
|
Child Development Disorders, Pervasive
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia.
|
28540026 |
2017 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association meta-analysis of 78,308 individuals identifies new loci and genes influencing human intelligence.
|
28530673 |
2017 |
|
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia.
|
28540026 |
2017 |
|
Reasoning
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association study of cognitive functions and educational attainment in UK Biobank (N=112 151).
|
27046643 |
2016 |
|
Parkinson Disease
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Despite several recent meta-analyses showing an association between several polymorphisms in genes related with detoxification mechanisms such as cytochrome P4502D6 (CYP2D6), and glutathione transferases M1 and T1 (GSTM1, and GSTT1), data on NAT2 gene polymorphisms obtained from the current meta-analysis do not support a major association with PD risk, except in Asian populations.
|
27216438 |
2016 |
|
Parkinson Disease
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Multivariate logistic regression analysis revealed that heterozygous genotypes of cytochrome P4502D6*4(CYP2D6*4), CYP2E1*5B (RsaI) polymorphism and homozygous mutant genotypes of CYP2E1*6 (Dra1) were found to be overrepresented in PD cases when compared to the controls.
|
18327668 |
2008 |
|
Parkinson Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
Cytochrome P4502D6 (debrisoquine 4-hydroxylase) and Parkinson's disease in Chinese and Caucasians.
|
10210913 |
1999 |
|
Parkinson Disease
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
The CYP2D6 B mutation may be involved in pathogenesis of LBV and PD in a dominant-negative manner, or in the linkage disequilibrium of the CYP2D microsatellite to another pathogenic gene locus.
|
9633694 |
1998 |
|
Agnosia for Pain
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Inhibiting the induced brain CYP2D reversed the change in oxycodone levels (1.2-fold; P > 0.1) and analgesia (1.1-fold; P > 0.3).
|
29266563 |
2019 |
|
Agnosia for Pain
|
0.020 |
Biomarker
|
disease |
BEFREE |
Inducing brain CYP2D with nicotine did not alter acute morphine analgesia (1.03-fold; p>0.8), or the rate of morphine tolerance (8.1%/day versus 7.6%; p>0.9).
|
28837793 |
2017 |
|
Hepatitis C
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Liver Kidney Microsomal autoantibody type 1(LKM1) directed to cytochrome P4502D6 (CYP2D6) characterises autoimmune hepatitis type-2 (AIH-2), but is also found in a proportion of chronic hepatitis C virus (HCV) infected patients, CYP2D6252-271 being a major B- cell autoepitope.
|
15000871 |
2004 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
We have refined the location of one possible tumour suppressor gene to the region between the microsatellite markers D22S299 and CYP2D.
|
10956388 |
2000 |
|
Hepatitis C
|
0.020 |
Biomarker
|
disease |
BEFREE |
Anti-liver-kidney microsome antibodies (anti-LKM) occur in autoimmune hepatitis (AIH) type II and in a subset of patients with hepatitis C. Anti-LKM1 in AIH are directed against cytochrome P4502D6 (CYP2D6), but conflicting data exist concerning the specificity of anti-LKM in hepatitis C. The aim of this study was to evaluate binding specificities of anti-LKM antibodies in both diseases using novel test antigens as well as their inhibitory capacity on CYP2D6 enzyme activity.
|
10540193 |
1999 |
|
Autoimmune Chronic Hepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Anti-liver-kidney microsome antibodies (anti-LKM) occur in autoimmune hepatitis (AIH) type II and in a subset of patients with hepatitis C. Anti-LKM1 in AIH are directed against cytochrome P4502D6 (CYP2D6), but conflicting data exist concerning the specificity of anti-LKM in hepatitis C. The aim of this study was to evaluate binding specificities of anti-LKM antibodies in both diseases using novel test antigens as well as their inhibitory capacity on CYP2D6 enzyme activity.
|
10540193 |
1999 |
|
Lewy Body Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The expression patterns of alternatively spliced forms of the CYP2D (6, 7, 7A, 7B) gene were analyzed in the brains of individuals with Lewy body disease (LBD) and correlated with CYP2D6 polymorphisms.
|
10534269 |
1999 |
|
Autoimmune hepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Anti-liver-kidney microsome antibodies (anti-LKM) occur in autoimmune hepatitis (AIH) type II and in a subset of patients with hepatitis C. Anti-LKM1 in AIH are directed against cytochrome P4502D6 (CYP2D6), but conflicting data exist concerning the specificity of anti-LKM in hepatitis C. The aim of this study was to evaluate binding specificities of anti-LKM antibodies in both diseases using novel test antigens as well as their inhibitory capacity on CYP2D6 enzyme activity.
|
10540193 |
1999 |
|
Malignant neoplasm of lung
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Taking this new information into account, we have reconsidered the potential influence of CYP2D6 polymorphism in lung cancer susceptibility by performing a comparative analysis of the overall mutational spectrum of CYP2D6 and of the rearrangements of CYP2D in 249 patients with lung cancer and in 265 control individuals matched on age, sex, hospital and residence area.
|
9511176 |
1998 |
|
Carcinoma of lung
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Taking this new information into account, we have reconsidered the potential influence of CYP2D6 polymorphism in lung cancer susceptibility by performing a comparative analysis of the overall mutational spectrum of CYP2D6 and of the rearrangements of CYP2D in 249 patients with lung cancer and in 265 control individuals matched on age, sex, hospital and residence area.
|
9511176 |
1998 |